Ilaris

Canakinumab, the active ingredient in Ilaris, is an interleukin‑1 beta (IL‑1β) inhibitor presented as a solution for subcutaneous injection for subcutaneous use. It selectively neutralises IL‑1β and is indicated for cryopyrin‑associated periodic syndromes, systemic juvenile idiopathic arthritis, adult‑onset Still’s disease, gout flares, and for reducing cardiovascular events in patients with a prior myocardial infarction. GNH USA supplies Ilaris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, transplant centres and clinics worldwide, with dedicated logistics for temperature‑controlled products and regulatory support.

Canakinumab is an interleukin‑1 beta inhibitor used in several autoinflammatory and immune‑mediated conditions. - Cryopyrin‑associated periodic syndromes (CAPS): reduces disease activity and frequency of flares. - Systemic juvenile idiopathic arthritis (SJIA): controls systemic inflammation and arthritis symptoms. - Adult‑onset Still’s disease: alleviates systemic symptoms and joint involvement. - Gout flares: provides rapid relief of acute gout attacks. - Prior myocardial infarction (CANTOS study): lowers risk of recurrent major adverse cardiovascular events.

Canakinumab may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Injection site reactions: pain, redness, or swelling at the injection site. - Upper respiratory tract infection: mild cold‑like symptoms. - Headache: transient mild to moderate headache. - Nausea: occasional mild nausea.

Serious or Rare Side Effects: - Serious infections: bacterial, viral or fungal infections requiring medical attention. - Neutropenia: marked reduction in neutrophil count, increasing infection risk. - Hypersensitivity reactions: anaphylaxis or severe allergic responses.

When using Ilaris, several precautions should be observed to ensure patient safety. - Infection risk: monitor for signs of bacterial, viral, or fungal infections. - Live vaccines: avoid administration during treatment due to immunosuppression. - Hematologic monitoring: perform regular complete blood counts, especially neutrophils. - Pregnancy and lactation: use only if potential benefit justifies potential risk; data limited. - Concomitant immunosuppressants: assess infection risk when combined with other immunosuppressive agents. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Canakinumab can interact with other medicines, requiring careful assessment.

Major Interactions (Avoid): - Live vaccines: contraindicated because canakinumab suppresses immune response. - Concurrent IL‑1 or IL‑6 biologics: combined use may markedly increase infection risk.

Moderate Interactions (Monitor Closely): - Other immunosuppressants (e.g., azathioprine, methotrexate): may enhance infection susceptibility, requiring monitoring. - Antimicrobial prophylaxis for latent tuberculosis: consider screening and treatment before initiating therapy. - CYP450 substrates: generally unaffected, but monitor if patient is on multiple drugs with narrow therapeutic windows.